GLP-1 class medications, widely prescribed for obesity and diabetes management, are effective in promoting weight reduction and improving various health indicators. However, recent research from the University of Virginia has unveiled a significant limitation: these drugs do not appear to enhance cardiorespiratory fitness (CRF), a critical long-term predictor of cardiovascular mortality. The findings were published in the Journal of Clinical Endocrinology & Metabolism.
An analysis of existing data indicates that patients undergoing GLP-1 therapy experience not only a reduction in fat tissue but also a considerable loss of lean body mass, including muscle. Experts estimate that up to 40% of the total weight lost could be attributed to muscle mass. This raises concerns, as decreased muscle mass is associated with an elevated risk of diminished physical function and may negatively impact long-term health prognoses.
The researchers emphasize the necessity of a comprehensive treatment strategy that incorporates regular physical activity, adequate protein intake, and controlled nutrition. Patients currently using GLP-1 medications are strongly advised to consult with their healthcare provider regarding strategies to preserve muscle mass and maintain cardiorespiratory endurance.
It was previously noted that semaglutide, another drug in this class, might be linked to a rare but serious adverse effect: anterior ischemic optic neuropathy, a condition that can result in partial or complete vision loss.
